1. Scrip
  2. >>Therapy Areas

Receptos radiant on top-line data for Gilenya rival

 
• By Mandy Jackson

Receptos jumped 32% in after-hours trading on 9 June after the San Diego-based company said its sphingosine-1-phosphate receptor 1 (S1P1) agonist RPC1063 met the primary endpoint of reduction in MRI brain lesion activity for multiple sclerosis patients enrolled in the Phase II portion of the Phase II/III RADIANCE clinical trial.

Receptos jumped 32% in after-hours trading on 9 June after the San Diego-based company said its sphingosine-1-phosphate receptor 1 (S1P1) agonist RPC1063 met the primary endpoint of reduction in MRI brain lesion activity for multiple sclerosis patients enrolled in the Phase II portion of the Phase II/III RADIANCE clinical trial.

Executives revealed few details, but indicated that the results so far "exceeded expectations" and showed a differentiated profile relative to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

More from Therapy Areas

Novartis’s Cosentyx Suffers Rare Phase III Fail

 
• By Kevin Grogan

Multi-blockbuster falls short in a giant cell arteritis study.

In Brief: 4DMT Fast-Tracks Long-Acting Wet AMD Therapy Trials, Cuts 25% Of Workforce

 
• By Sushmita Panda

4D Molecular Therapeutics has fast-tracked its Phase III trials for 4D-150 in wet AMD, with top-line data from one now expected in H1 2027 and another underway ahead of schedule. The company is also cutting a quarter of its staff as it focuses on its late-stage pipeline and to help fund the trials.

Regeneron Wins Long-Sought FDA Nod For Lynozyfic In Myeloma

 
• By Alaric DeArment

The agency gave accelerated approval to the BCMAxCD3-directed bispecific antibody, which had been the subject of an August 2024 CRL.